The concept of syndromic diagnoses of osteoarthritis and back pain as a cause of therapy failure
https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.104
Abstract
Osteoarthritis is considered a peripheral joint disease and is often ignored when discussing the prevalence and treatment of back pain. Traditionally, clinical guidelines from various countries are devoted to the treatment of nonspecific back pain (lower back pain), although this diagnosis is syndromic and is absent in ICD-10. Therefore, in real clinical practice, such diagnoses as osteochondrosis and dorsopathy simultaneously exist. The treatment strategies for back pain do not take into account chronic inflammation directly related to pro-inflammatory cytokines and oxidative stress, which makes drug therapy ineffective. It is advisable from the first days of therapy to choose parenteral forms from the group of symptomatic slow-acting drugs containing chondroitin sulfate (Chondroguard®), which will accelerate the onset of the analgesic effect and increase the effectiveness of pathogenetic therapy.
About the Authors
M. V. Putilina
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Marina V. Putilina – Dr. Med. Sc., Professor, Chair of Clinical Pharmacology, Faculty of Medicine
Scopus Author ID: 9747828500; RSCI SPIN-code: 8480-9561
1 Ostrovityanov Str., Moscow 117997, Russia
N. V. Teplova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Natalia V. Teplova – Dr. Med. Sc., Professor, Chief of Chair of Clinical Pharmacology, Faculty of Medicine
RSCI SPIN-code: 9056-1948
1 Ostrovityanov Str., Moscow 117997, Russia
O. S. Gerasimova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Olga S. Gerasimova – Assistant Professor, Chair of Clinical Pharmacology, Faculty of Medicine
1 Ostrovityanov Str., Moscow 117997, Russia
References
1. Goode A.P., Carey T.S., Jordan J.M. Low back pain and lumbar spine osteoarthritis: how are they related? Curr Rheumatol Rep. 2013; 15 (2): 305. https://doi.org/10.1007/s11926-012-0305-z.
2. Hunter D.J., March L., Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. 2020; 396 (10264): 1711–12. https://doi.org/10.1016/S0140-6736(20)32230-3.
3. Ramanathan S., Hibbert P., Wiles L., et al. What is the association between the presence of comorbidities and the appropriateness of care for low back pain? A population-based medical record review study. BMC Musculoskelet Disord. 2018; 19 (1): 391. https://doi.org/10.1186/s12891-018-2316-z.
4. Putilina M.V. Dorsopathies: differential diagnosis and treatment. Spravochnik poliklinicheskogo vracha / Outpatient Doctor's Handbook. 2007; 5: 4–10 (in Russ.).
5. Varlotta G.P., Lefkowitz T.R., Schweitzer M., et al. The lumbar facet joint: a review of current knowledge: part 1: anatomy, biomechanics, and grading. Skeletal Radiol. 2011; 40 (1): 13–23. https://doi.org/10.1007/s00256-010-0983-4.
6. Goode A.P., Carey T.S., Jordan JM. Low back pain and osteoarthritis of the lumbar spine: how are they related? Curr Rheumatol Rep. 2013; 15 (2): 305. https://doi.org/10.1007/s11926-012-0305-z.
7. Itz C.J., Geurts J.W., Kleef M.V. Clinical course of non-specific low back pain: a systematic review of prospective cohort studies set in primary care. Eur J Pain. 2013; 17 (1): 5–15. https://doi.org/10.1002/j.1532-2149.2012.00170.x.
8. Ramanathan S., Hibbert P., Wiles L., et al. What is the association between the presence of comorbidities and the appropriateness of care for low back pain? A population-based medical record review study. BMC Musculoskelet Disord. 2018; 19 (1): 391. https://doi.org/10.1186/s12891-018-2316-z.
9. Alekseeva L.I., Taskina E.A., Kashevarova N.G. Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment. Sovremennaya revmatologiya / Modern Rheumatology Journal. 2019; 13 (2): 9–21 (in Russ.). https://doi.org/10.14412/1996-7012-2019-2-9-21.
10. Hashimoto K., Akagi M. The role of oxidation of low-density lipids in pathogenesis of osteoarthritis: a narrative review. J Int Med Res. 2020; 48 (6): 300060520931609. https://doi.org/10.1177/0300060520931609.
11. Wojdasiewicz P., Poniatowski Ł.A., Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014; 2014: 561459. https://doi.org/10.1155/2014/561459.
12. Komatsu N., Takayanagi H. Inflammation and bone destruction in arthritis: synergistic activity of immune and mesenchymal cells in joints. Front Immunol. 2012; 3: 77. https://doi.org/10.3389/fimmu.2012.00077.
13. Putilina M.V. Endothelium as a target for new therapeutic strategies in cerebral vascular diseases. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2017; 117 (10): 122–30 (in Russ.). https://doi.org/10.17116/jnevro2017117101122-130.
14. Putilina M.V., Teplova N.V., Gromova O.A., et al. Motor dysfunction in elderly patients with chronic musculoskeletal system diseases (locomotive syndrome). Neurology, Neuropsychiatry, Psychosomatics. 2021; 13 (2): 130–6 (in Russ.). https://doi.org/10.14412/2074-2711-2021-2-130-136.
15. de Rooij M., van der Leeden M., Heymans M.W., et al. Prognosis of pain and physical functioning in patients with knee osteoarthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2016; 68 (4): 481–92. https://doi.org/10.1002/acr.22693.
16. Putilina M.V., Ivanova M.P., Petrikeyeva A.E., Burns S.A. Difficulties in diagnosing sacroiliitis in young patients Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 202; 120 (8): 117–26 (in Russ.). https://doi.org/10.17116/jnevro2020120081117.
17. Raymuev K.V., Ishchenko A.M., Malyshev M.E. Pro-inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Herald of North-Western State Medical University Named After I.I. Mechnikov. 2018; 10 (3): 19–27 (in Russ.). https://doi.org/10.17816/mechnikov201810319-27.
18. Putilina M.V., Teplova N.V. Drug safety as a priority area of Russian medicine. Lechebnoye delo / General Medicine. 2019; 4: 7–14 (in Russ.). https://doi.org/10.24411/2071-5315-2019-12152.
19. Karateev A.E., Nasonov E.L., Ivashkin V.T., et al. Rational use of non-steroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018; 56 (Suppl. 1): 1–29(in Russ.). https://doi.org/10.14412/1995-4484-2018-1-29.
20. Saragiotto B.T., Machado G.C., Ferreira M.L., et al. Paracetamol for low back pain. Cochrane Database Syst Rev. 2016; 2016 (6): CD012230. https://doi.org/10.1002/14651858.CD012230.
21. Koes B., Schreijenberg M., Tkachev A. Paracetamol for low back pain: the state of the research field. Expert Rev Clin Pharmacol. 2020; 13 (9): 1059–66. https://doi.org/10.1080/17512433.2020.1817738.
22. Putilina M.V. Osteoarthritis in the practice of a neurologist: old and new features. Consilium Medicum. Neurology and Rheumatology. 2016; 1: 66–9 (in Russ.).
23. du Souich P., García A.G., Vergés J., Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med. 2009; 13 (8A): 1451–63. https://doi.org/10.1111/j.1582-4934.2009.00826.x.
24. Egea J., García A.G., Verges J., et al. Antioxidant, antiinflammatory and neuroprotective actions of chondroitin sulfate and proteoglycans. Osteoarthritis Cartilage. 2010; 18 (Suppl. 1): S24–7. https://doi.org/10.1016/j.joca.2010.01.016.
25. Henrotin Y., Lambert C. Chondroitin and glucosamine in the management of osteoarthritis: an update. Curr Rheumatol Rep. 2013; 15 (10): 361. https://doi.org/10.1007/s11926-013-0361-z.
26. Honvo G., Bruyère O., Geerinck A., et al. Efficacy of chondroitin sulfate in patients with knee osteoarthritis: a comprehensive meta analysis exploring inconsistencies in randomized, placebo-controlled trials. Adv Ther. 2019; 36 (5): 1085–99. https://doi.org/10.1007/s12325-019-00921-w.
27. Beaudart C., Lengelé L., Leclercq V., et al. Symptomatic efficacy of pharmacological treatments for knee osteoarthritis: a systematic review and a network meta-analysis with a 6-month time horizon. Drugs. 2020; 80 (18): 1947–59. https://doi.org/10.1007/s40265-020-01423-8.
28. Kolasinski S.L., Neogi T., Hochberg M.C., et al. 2019 American College of Rheumatology/Arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2020; 72 (2): 149–62. https://doi.org/10.1002/acr.24131.
29. Gromova O.A., Torshin I.Yu., Zaychik B.Ts., et al. Differences in the standardization of medicinal products based on extracts of chondroitin sulfate. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmaco economics and Pharmacoepidemiology. 2021; 14 (1): 50–62 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.083.
30. Torshin I.Yu., Lila A.M., Naumov A.V., et al. Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmako epidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (4): 388–99. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066.
31. Register of Medicinal Products of Russia. Chondroguard®. Available at: https://www.rlsnet.ru/tn_index_id_42802.htm (in Russ.) (accessed 16.08.2021).
Review
For citations:
Putilina M.V., Teplova N.V., Gerasimova O.S. The concept of syndromic diagnoses of osteoarthritis and back pain as a cause of therapy failure. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(3):407-414. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.104
Views:
570
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 